Tissue factor pathway inhibitor-2; Acute myelocytic leukemia; VEGF; leukemia.

In recent animal studies, this chemical inhibited COX-2, a protein that spurs inflammation (the same protein that so-called COX-2 inhibitor drugs such as Celebrex quash).

However, patients with a prior MI may be at increased risk for experiencing another if they use either COX-2-selective inhibitor, the research indicates.